Vikas Sinha - 16 Aug 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Officer Title: President and Chief Financial Officer, Director
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol
ALVR
Transactions as of
16 Aug 2022
Transactions value $
$0
Form type
4
Filing time
17 Aug 2022, 18:04:02 UTC
Previous filing
01 Aug 2022
Next filing
24 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $0 +100,000 +11% $0 1,038,224 16 Aug 2022 Direct F1
holding ALVR Common Stock 16,674,766 16 Aug 2022 By ElevateBio LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2 Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Officer Title: President and Chief Financial Officer